Evidence map›Paper›PMID 30788585›Full record

ArticleActa neuropathologica2019

Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms.

Maria Masnata, Giacomo Sciacca, Alexander Maxan, Luc Bousset, Hélèna L Denis, Florian Lauruol, Linda David, Martine Saint-Pierre, Jeffrey H Kordower, Ronald Melki and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Detection of antibodies against the huntingtin protein in human plasma.Cellular and molecular life sciences : CMLS · 2023
    Article
  11. Article
  12. Article
  13. Review
  14. Passive immunization against phosphorylated tau improves features of Huntington's disease pathology.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Maria MasnataCentre de Recherche du CHU de Québec, Axe Neurosciences, 2705 Boulevard Laurier, Québec, QC, G1V 4G2, Canada.
Giacomo SciaccaCentre de Recherche du CHU de Québec, Axe Neurosciences, 2705 Boulevard Laurier, Québec, QC, G1V 4G2, Canada.
Alexander MaxanCentre de Recherche du CHU de Québec, Axe Neurosciences, 2705 Boulevard Laurier, Québec, QC, G1V 4G2, Canada.
Luc BoussetLaboratory of Neurodegenerative Diseases, Institut François Jacob, MIRCen, CEA, CNRS, 18 Route du Panorama, 92265, Fontenay-aux-Roses Cedex, France.
Hélèna L DenisCentre de Recherche du CHU de Québec, Axe Neurosciences, 2705 Boulevard Laurier, Québec, QC, G1V 4G2, Canada.
Florian LauruolCentre de Recherche du CHU de Québec, Axe Neurosciences, 2705 Boulevard Laurier, Québec, QC, G1V 4G2, Canada.
Linda DavidCentre de Recherche du CHU de Québec, Axe Neurosciences, 2705 Boulevard Laurier, Québec, QC, G1V 4G2, Canada.
Martine Saint-PierreCentre de Recherche du CHU de Québec, Axe Neurosciences, 2705 Boulevard Laurier, Québec, QC, G1V 4G2, Canada.
Jeffrey H KordowerDepartment of Neurological Sciences, Rush University Medical Centre, Chicago, IL, USA.
Ronald MelkiLaboratory of Neurodegenerative Diseases, Institut François Jacob, MIRCen, CEA, CNRS, 18 Route du Panorama, 92265, Fontenay-aux-Roses Cedex, France. ronald.melki@cnrs.fr.
Melanie AlpaughCentre de Recherche du CHU de Québec, Axe Neurosciences, 2705 Boulevard Laurier, Québec, QC, G1V 4G2, Canada. melanie-jeanne.alpaugh.1@ulaval.ca.
Francesca CicchettiCentre de Recherche du CHU de Québec, Axe Neurosciences, 2705 Boulevard Laurier, Québec, QC, G1V 4G2, Canada. francesca.cicchetti@crchul.ulaval.ca.
Centre hospitalier universitaire de Québec · CAUniversité Laval · CACommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRDirection de la Recherche Fondamentale · FRRush University Medical Center · US

Funding

CIHR
6 · The paper itself

Abstract

In recent years, evidence has accumulated to suggest that mutant huntingtin protein (mHTT) can spread into healthy tissue in a prion-like fashion. This theory, however, remains controversial. To fully address this concept and to understand the possible consequences of mHTT spreading to Huntington's disease pathology, we investigated the effects of exogenous human fibrillar mHTT (Q48) and huntingtin (HTT) (Q25) N-terminal fragments in three cellular models and three distinct animal paradigms. For in vitro experiments, human neuronal cells [induced pluripotent stem cell-derived GABA neurons (iGABA) and (SH-SY5Y)] as well as human THP1-derived macrophages, were incubated with recombinant mHTT fibrils. Recombinant mHTT and HTT fibrils were taken up by all cell types, inducing cell morphology changes and death. Variations in HTT aggregation were further observed following incubation with fibrils in both THP1 and SH-SY5Y cells. For in vivo experiments, adult wild-type (WT) mice received a unilateral intracerebral cortical injection and R6/2 and WT pups were administered fibrils via bilateral intraventricular injections. In both protocols, the injection of Q48 fibrils resulted in cognitive deficits and increased anxiety-like behavior. Post-mortem analysis of adult WT mice indicated that most fibrils had been degraded/cleared from the brain by 14 months post-surgery. Despite the absence of fibrils at these later time points, a change in the staining pattern of endogenous HTT was detected. A similar change was revealed in post-mortem analysis of the R6/2 mice. These effects were specific to central administration of fibrils, as mice receiving intravenous injections were not characterized by behavioral changes. In fact, peripheral administration resulted in an immune response mounting against the fibrils. Together, the in vitro and in vivo data indicate that exogenously administered mHTT is capable of both causing and exacerbating disease pathology.

Indexed as

Protein AggregatesAnimalsAnxietyBrainCell Line, TumorCognition DisordersExonsExploratory BehaviorFemaleGABAergic NeuronsHumansHuntingtin ProteinInduced Pluripotent Stem CellsInjectionsInjections, IntraventricularMaleHTT protein, humanHuntingtin ProteinProtein AggregatesRecombinant Proteins

Identifiers

PMID30788585
PMCPMC6531424
OpenAlexW2916640091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.